17 completed, 2 active not recruiting, 1 recruiting, 1 withdrawn. 9 Phase 3, 7 Phase 2, 5 Phase 1, 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 9 | Completed 8, Active not recruiting 1 |
| Phase 2 | 7 | Completed 5, Active not recruiting 1, Withdrawn 1 |
| Phase 1 | 5 | Completed 5 |
| Phase 4 | 2 | Completed 1, Recruiting 1 |
Follow moxidectin: new trials by email Literature Review of moxidectin trials Research Report on moxidectin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Moxidectin Versus Ivermectin as Mass Drug Administration for the Control of Onchocerciasis and Other Neglected Tropical Diseases Moxidectin, Ivermectin - Onchocerciasis, Ascaris Lumbricoides Infection | Phase 4 | Recruiting | Kirby Institute | 52000 | 2025-08-04 | 2025-11-21 |
| Study of the Safety and Efficacy of Moxidectin Tablets for the Reduction of Demodex Eyelash Infestation Moxidectin 2 MG Oral Tablet, Placebo - Blepharitis | Phase 4 | Completed | Eye Research Foundation, Inc. | 24 | 2025-02-02 | 2025-08-12 |
| Efficacy and Safety of Moxidectin-Albendazole Co-administration in SAC Moxidectin 2 mg Oral Tablet, Albendazole 400 mg Oral Tablet, Placebo Moxidectin - Trichuriasis, Ascariasis | Phase 3 | Completed | Jennifer Keiser | 224 | 2024-05-14 | 2025-09-19 |
| Safety and Efficacy of Novel Combination Regimens for Treatment of Onchocerciasis Ivermectin w/ Albendazole, Ivermectin + Diethylcarbamazine + Albendazole, Moxidectin + Albendazole - Onchocercal Subcutaneous Nodule, Onchocerciasis | Phase 2 | Active not recruiting | Washington University School of Medicine | 300 | 2024-04-05 | 2025-12-18 |
| Clinical Trial Evaluating the Safety and Efficacy of Moxidectin 2 mg Ivermectin-controlled in Loa Loa Microfilaremic Patients Moxidectin 2 MG Oral Tablet, Ivermectin 3Mg Tab, Placebo oral tablet - Onchocerciasis, Ocular, Loiasis | Phase 2 | Completed | Center for Research on Filariasis and Other Tropical Diseases, Cameroon | 72 | 2022-04-07 | 2025-02-24 |
| Efficacy and Safety of Moxidectin Versus Ivermectin Against Strongyloides Stercoralis Moxidectin 2 mg, Ivermectin 3 mg, Placebo - Strongyloides Stercoralis Infection | Phase 3 | Completed | Jennifer Keiser | 332 | 2022-02-05 | 2024-01-25 |
| Efficacy and Safety of MOX/ALB Co-administration Moxidectin 2 mg Oral Tablet, Albendazole 400 mg Oral Tablet, Ivermectin 3 mg Oral Tablet - Trichuriasis, Ascariasis | Phase 3 | Completed | Jennifer Keiser | 255 | 2021-06-15 | 2024-01-24 |
| Safety and Efficacy of Annual or Biannual Doses of Moxidectin or Ivermectin for Onchocerciasis Moxidectin, Ivermectin - Onchocerciasis | Phase 3 | Active not recruiting | Medicines Development for Global Health | 323 | 2021-05-03 | 2025-12-23 |
| Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant Albendazole Moxidectin, Ivermectin, Albendazole - Onchocerciasis | Phase 3 | Completed | Medicines Development for Global Health | 12979 | 2021-05-03 | 2026-03-03 |
| A Pharmacokinetic and Safety Study of Moxidectin to Identify an Optimal Dose for Treatment of Children 4 to 11 Years Moxidectin - Onchocerciasis | Phase 1 | Completed | Medicines Development for Global Health | 36 | 2021-03-29 | 2025-09-05 |
| Efficacy and Safety of MOX/ALB vs. IVM/ALB Co-administration moxidectin (8 mg) / albendazole (400 mg), ivermectin (200 µg/kg) / albendazole (400 mg), ALBENDAZOLE 400 Mg ORAL TABLET [ZENTEL] - Trichuriasis, Ascariasis | Phase 2 / Phase 3 | Completed | Jennifer Keiser | 536 | 2021-03-01 | 2024-12-05 |
| Moxidectin for LF, Cote d'Ivoire (DOLF) Ivermectin, Diethylcarbamazine, Albendazole - Lymphatic Filariasis | Phase 3 | Completed | Washington University School of Medicine | 164 | 2020-08-20 | 2026-01-29 |
| Efficacy, Safety, and PK of Ascending Dosages of Moxidectin Versus Ivermectin Against Strongyloides Stercoralis Moxidectin, Ivermectin, Placebo oral tablet - Strongyloides Stercoralis Infection | Phase 2 / Phase 3 | Completed | Jennifer Keiser | 617 | 2019-11-27 | 2024-12-09 |
| Efficacy and Safety of Ascending Dosages of Moxidectin and Moxidectin-albendazole Against Trichuris Trichiura Moxidectin 8mg, Moxidectin 8 mg + albendazole 400 mg, Moxidectin 16 mg - Trichuris Trichiura; Infection | Phase 2 | Completed | Swiss Tropical & Public Health Institute | 286 | 2018-07-03 | 2018-08-14 |
| Effect of a Single Oral Dose of Moxidectin on the Cardiac QT Interval of Healthy Volunteers Moxidectin, Placebo - QT Effects in Healthy Volunteers | Phase 1 | Completed | Medicines Development for Global Health | 60 | 2017-01-01 | 2019-03-14 |
| Pediatric Pharmacokinetics And Safety Study Of Moxidectin moxidectin - Onchocerciasis | Phase 2 | Withdrawn | Pfizer | 2011-04-01 | 2012-03-29 | |
| Study Evaluating The Co-Administration Of Moxidectin And Midazolam In Healthy Subjects Moxidectin, Midazolam - Healthy | Phase 1 | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | 38 | 2009-04-01 | 2010-09-16 |
| Study Comparing Moxidectin And Ivermectin In Subjects With Onchocerca Volvulus Infection Moxidectin, Ivermectin - Onchocerciasis | Phase 3 | Completed | Medicines Development for Global Health | 1497 | 2009-04-01 | 2018-01-31 |
| Study Evaluating The Excretion Of Moxidectin Into The Breast Milk Of Lactating, Non-Breastfeeding Women Moxidectin - Infection | Phase 1 | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | 12 | 2008-11-01 | 2010-09-16 |
| Study Evaluating The Effect Of High-Fat Meal On Bioavailability And Pharmacokinetics Of Single Dose Of Moxidectin moxidectin - Infection | Phase 1 | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | 54 | 2008-11-01 | 2011-02-15 |
Showing 20 of 21. Sign in to see all of them.
Onchocerciasis (8) · Onchocerciasis, Ocular (5) · Trichuriasis (5) · Hookworm Infections (4) · Ancylostomiasis (3) · Ascariasis (3) · Infections (2) · Blepharitis (1) · Elephantiasis, Filarial (1) · Helminthiasis (1) · Intestinal Diseases, Parasitic (1) · Loiasis (1) · Scabies (1)
Medicines Development for Global Health (6) · Jennifer Keiser (5) · Wyeth is now a wholly owned subsidiary of Pfizer (3) · Washington University School of Medicine (2) · Center for Research on Filariasis and Other Tropical Diseases, Cameroon (1) · Eye Research Foundation, Inc. (1) · Kirby Institute (1) · Pfizer (1) · Swiss Tropical & Public Health Institute (1)
Côte d’Ivoire (3) · Democratic Republic of the Congo (3) · Ghana (3) · Tanzania (3) · Liberia (2) · United States (2) · Angola (1) · Cambodia (1) · Cameroon (1) · France (1) · Germany (1) · Laos (1) · United Kingdom (1)
Benjamin Koudou, PhD (2) · Tony Ukety, MD, DO, MPH (2) · Catherine Bjerum, MD, MPH (1) · Gary Weil, MD (1) · Jennifer Keiser, Prof. Dr (1) · Jennifer Keiser, Prof. Dr. (1) · Mark Sullivan (1) · Nicholas O Opoku, MD (1) · Nicholas Opoku, MD (1) · Patrick Kpanyen, PhD (1) · Peter Fischer, PhD (1) · Philip Budge, MD, PhD (1)
PMID 37949090, PMID 24968000, PMID 29361335, PMID 30117300, PMID 31044235, PMID 33798487, PMID 34296417, PMID 34632308, PMID 35476631, PMID 36354034, PMID 37357904, PMID 37616301, PMID 37721964, PMID 38966851, PMID 40345209, PMID 40675166, PMID 40707999, PMID 42848323